MedTrace Logo

A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®

NCT00356421 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2009-09-02

Study results available
· View outcomes & findings →

Summary

To compare efficacy and safety of Exubera® vs Humalog in patients with type 1 diabetes mellitus

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Inhaled Human Insulin (Exubera®)

Preprandial inhaled insulin regimen and administration of insulin glargine QD

DRUG

Insulin lispro (Humalog)

Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States
  • Austria
  • Belgium
  • Denmark
  • Finland
  • France
  • Ireland
  • Netherlands
  • Norway
  • Portugal
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00356421 on ClinicalTrials.gov